Evigrade
Critical

Apixaban × Rifampicin

Direct oral anticoagulants (factor Xa inhibitors)×Antituberculous antibiotic

Mechanism

Rifampicin is the strongest clinical inducer of CYP3A4 and P-glycoprotein. Apixaban levels fall by 54%, anticoagulation lost. FDA recommends avoiding the combination.

Symptoms

Ischemic stroke or recurrent VTE on apparently active apixaban. Lab: low anti-Xa level.

Management

Combination contraindicated. For tuberculosis treatment in an atrial fibrillation patient, use warfarin with target INR 2.5–3.5 and more frequent monitoring (rifampicin also induces CYP2C9 and weakens warfarin – higher doses needed).

Check the full regimen, not just this pair

Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.

Open checker

Sources

All interactions